“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。
"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.
机构信息
Department of Cardiology, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Naples, Italy.
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
出版信息
Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.
Abstract
Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation.
摘要
瓣膜性心脏病和心房颤动常常并存。几十年来，口服维生素 K 拮抗剂一直是这种情况下抗血栓预防的主要抗凝管理方法。新型直接口服抗凝剂（DOACs）是一类新药，目前由于其疗效和安全性已得到充分证实，是治疗非瓣膜性心房颤动的主要选择。一些新的证据正在探索 DOAC 在瓣膜性心房颤动（机械和生物假体瓣膜）患者中的作用。在这篇综述中，我们探讨了医学文献中可用的数据，以确定 DOAC 在瓣膜性心脏病和心房颤动患者中的实际作用。
相似文献
1
"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。
Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.
2
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
3
Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?直接口服抗凝剂可否用于预防瓣膜性心房颤动患者的卒中？
Curr Cardiol Rep. 2019 Aug 31;21(10):118. doi: 10.1007/s11886-019-1199-4.
4
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis.除重度二尖瓣狭窄和机械瓣膜外的心房颤动合并瓣膜性心脏病患者使用直接口服抗凝剂的荟萃分析。
Circulation. 2017 Feb 14;135(7):714-716. doi: 10.1161/CIRCULATIONAHA.116.026793.
5
Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.心房颤动合并心脏瓣膜异常患者的卒中预防策略：对“瓣膜性”心房颤动的认知：欧洲心律协会调查结果
Europace. 2016 Oct;18(10):1593-1598. doi: 10.1093/europace/euw302.
7
Unresolved issues in the use of direct acting oral anticoagulants.直接作用口服抗凝剂使用中的未解决问题。
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(12):913-921. doi: 10.1080/14779072.2023.2271388. Epub 2023 Dec 13.
8
[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation].非瓣膜性心房颤动患者使用直接口服抗凝剂预防卒中
Dtsch Med Wochenschr. 2015 May;140(10):750-5. doi: 10.1055/s-0041-102000. Epub 2015 May 13.
9
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.非维生素K口服抗凝剂用于特殊人群房颤患者的卒中预防
Adv Ther. 2017 Jun;34(6):1283-1290. doi: 10.1007/s12325-017-0550-7. Epub 2017 May 10.
10
Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease.直接口服抗凝剂在心房颤动和心脏瓣膜病患者中的应用。
JAAPA. 2022 Sep 1;35(9):17-18. doi: 10.1097/01.JAA.0000854516.90788.a8.
引用本文的文献
1
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Mechanical Heart Valves: A Systematic Review.直接口服抗凝剂与华法林在机械心脏瓣膜患者中的有效性和安全性：一项系统评价。
Cureus. 2025 Aug 10;17(8):e89736. doi: 10.7759/cureus.89736. eCollection 2025 Aug.
2
Long-Term Outcomes of Mechanical Versus Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis.机械瓣与生物瓣主动脉瓣置换术的长期结局：一项系统评价和荟萃分析
Cureus. 2024 Jan 19;16(1):e52550. doi: 10.7759/cureus.52550. eCollection 2024 Jan.
3
Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials.来源于实践的数据用于非维生素K拮抗剂口服抗凝治疗，以补充随机试验的观察结果。
Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I1-I12. doi: 10.1093/eurheartj/suaa100. eCollection 2020 Sep.
本文引用的文献
1
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.阿哌沙班对比华法林在伴有既往生物瓣置换或修复的心房颤动患者中的疗效和安全性：来自 ARISTOTLE 试验的结果。
Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9.
2
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.达比加群酯与维生素 K 拮抗剂治疗心房颤动患者三联抗栓治疗的安全性和有效性：一项初步研究。
Biomed Res Int. 2019 Feb 13;2019:5473240. doi: 10.1155/2019/5473240. eCollection 2019.
3
Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late.直接口服抗凝剂在 80 岁以上的房颤患者中的应用：永远不会太晚。
J Cardiovasc Pharmacol. 2019 Apr;73(4):207-214. doi: 10.1097/FJC.0000000000000661.
4
Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study.在心房颤动患者中持续使用阿哌沙班：一项回顾性多中心研究。
J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):66-73. doi: 10.2459/JCM.0000000000000744.
5
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study.利伐沙班与华法林在机械心脏瓣膜患者中的比较：RIWA 研究的原理和设计。
Drugs R D. 2018 Dec;18(4):303-308. doi: 10.1007/s40268-018-0249-5.
6
Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review.心房颤动与恶性肿瘤：非维生素 K 口服抗凝剂的临床表现——系统评价。
Semin Thromb Hemost. 2019 Mar;45(2):205-214. doi: 10.1055/s-0038-1661386. Epub 2018 Aug 17.
7
Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis.利伐沙班在接受机械二尖瓣置换术的孤立性二尖瓣置换术后患者中的应用的有效性和安全性。
Am J Cardiol. 2018 Sep 15;122(6):1047-1050. doi: 10.1016/j.amjcard.2018.06.015. Epub 2018 Aug 8.
9
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.2018 年欧洲心脏病学会实用指南：非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中的应用：执行摘要。
Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054.
10
Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.非维生素 K 拮抗剂口服抗凝剂在心房颤动和生物瓣心脏瓣膜/既往手术瓣膜修复患者中的应用：一项多中心临床实践经验。
Semin Thromb Hemost. 2018 Jun;44(4):364-369. doi: 10.1055/s-0037-1615261. Epub 2018 Jan 5.
Zotero 插件